L- and T-type calcium channels control aldosterone production from human adrenals

Abstract

Journal of Endocrinology244:1 237-247 T Yang, M He et al. Ca 2+ channels control aldosterone secretion AbstractAldosterone, which plays a key role in the regulation of blood pressure, is produced by zona glomerulosa (ZG) cells of the adrenal cortex. Exaggerated overproduction of aldosterone from ZG cells causes primary hyperaldosteronism. In ZG cells, calcium entry through voltage-gated calcium channels plays a central role in the regulation of aldosterone secretion. Previous studies in animal adrenals and human adrenal adrenocortical cell lines suggest that the T-type but not the L-type calcium channel activity drives aldosterone production. However, recent clinical studies show that somatic mutations in L-type calcium channels are the second most prevalent cause of aldosterone-producing adenoma. Our objective was to define the roles of T and L-type calcium channels in regulating aldosterone secretion from human adrenals. We find that human adrenal ZG cells mainly express T-type Ca V 3.2/3.3 and L-type Ca V 1.2/1.3 calcium channels. TTA-P2, a specific inhibitor of T-type calcium channel subtypes, reduced basal aldosterone secretion from acutely prepared slices of human adrenals. Surprisingly, nifedipine, the prototypic inhibitor of L-type calcium channels, also decreased basal aldosterone secretion, suggesting that L-type calcium channels are active under basal conditions. In addition, TTA-P2 or nifedipine also inhibited aldosterone secretion stimulated by angiotensin II-or elevations in extracellular K + . Remarkably, blockade of either L-or T-type calcium channels inhibits basal and stimulated aldosterone production to a similar extent. Low concentrations of TTA-P2 and nifedipine showed additive inhibitory effect on aldosterone secretion. We conclude that T-and L-type calcium channels play equally important roles in controlling aldosterone production from human adrenals.caused by autonomous overproduction of aldosterone, is the most common form of secondary endocrine hypertension (Stowasser 2001). Approximately 10% of hypertensive patients have PA (Rossi et al. 2006,

Targeting microglia L‐type voltage‐dependent calcium channels for the treatment of central nervous system disorders

“…Cav1.1 is largely restricted to skeletal muscle, where it is essential for excitationcontraction coupling; Cav1.2 and Cav1.3 also regulate excitationcontraction coupling in cardiac myocytes and smooth muscle cells (Lipscombe et al, 2004). Cav1 L-VDCCs are also localized to endocrine cells (Schulla et al, 2003;Yang, He, Zhang, Barrett, & Hu, 2019) as well as lymphoid and myeloid immune cells (Davenport, Li, Heizer, Schmitz, & Perraud, 2015;Komoda, Shiraki, Oyama, Nishikido, & Node, 2018;Suzuki, Inoue, & Ra, 2012) which express all Cav1 subtypes at varying levels (Choi et al, 2019; Komoda et al, 2018; Sharma et al, 2016). Timothy syndrome (TS), a rare autosomal-dominant disorder affecting multiple organ systems, demonstrates the importance of Cav1.2 throughout the body: mutations in CACNA1C, the gene encoding Cav1.2, lead to heart arrhythmias and structural cardiac defects, immune system dysfunction, neurodevelopmental difficulties such as ASD, and physical malformations such as syndactyly (Dixon, Cheng, Mercado, & Santana, 2012;Liao & Soong, 2010;Splawski et al, 2004).…”

Association Between Variants in Calcineurin Inhibitor Pharmacokinetic and Pharmacodynamic Genes and Renal Dysfunction in Adult Heart Transplant Recipients

“…In exploratory analyses, we found carriers of the CACNA1D rs893365 variant T allele had lower odds of renal dysfunction 1-year post-transplant. CACNA1D encodes a subunit of the calcium channel, Ca v 1.3, which plays an important role in the production and secretion of aldosterone from the adrenal cortex ( Yang et al, 2020 ). Aldosterone increases sodium and fluid retention which, in turn, results in higher blood pressure as part of renin-angiotensin-aldosterone system (RAS) activation.…”

Advances in Medical Treatment of Primary Aldosteronism

“…Genetic research has provided more insights into the targeted treatment with calcium channel blockers in PA patients. Recent studies have revealed that a certain dose of calcium channel blockers can block the KCNJ5 mutation channel and reduce the secretion of aldosterone 36,37 . An in vitro study in 2014 suggested that mutant GIRK4 channels differed from wild-type channels in pharmacological effects and could be blocked by CCBs.…”